NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01765088,A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas,https://clinicaltrials.gov/study/NCT01765088,,UNKNOWN,"This study is being conducted to help determine whether the addition of Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in vivo and vitro, when given along with temozolomide during the monthly cycles that follow radiation, is able to delay tumor growth, shrink tumors, or impact how long people with newly diagnosed high-grade glioma.",NO,Anaplastic Oligoastrocytoma|Anaplastic Astrocytoma|Glioblastoma,DRUG: Temozolomide|DRUG: α-IFN,"Over-all survival, 5-year","Quality of life, 5-year",,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CSNO2012001,2012-09,2017-12,2019-12,2013-01-10,,2018-02-23,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China",
